These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24751518)

  • 1. Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.
    Arai M; Tsukiyama-Kohara K; Takagi A; Tobita Y; Inoue K; Kohara M
    Biochem Biophys Res Commun; 2014 May; 448(1):56-62. PubMed ID: 24751518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
    Puyang X; Poulin DL; Mathy JE; Anderson LJ; Ma S; Fang Z; Zhu S; Lin K; Fujimoto R; Compton T; Wiedmann B
    Antimicrob Agents Chemother; 2010 May; 54(5):1981-7. PubMed ID: 20176894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.
    Fernandes F; Ansari IU; Striker R
    PLoS One; 2010 Mar; 5(3):e9815. PubMed ID: 20352119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.
    Chatterji U; Lim P; Bobardt MD; Wieland S; Cordek DG; Vuagniaux G; Chisari F; Cameron CE; Targett-Adams P; Parkinson T; Gallay PA
    J Hepatol; 2010 Jul; 53(1):50-6. PubMed ID: 20451281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.
    Robida JM; Nelson HB; Liu Z; Tang H
    J Virol; 2007 Jun; 81(11):5829-40. PubMed ID: 17376913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
    Mathy JE; Ma S; Compton T; Lin K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
    Fernandes F; Poole DS; Hoover S; Middleton R; Andrei AC; Gerstner J; Striker R
    Hepatology; 2007 Oct; 46(4):1026-33. PubMed ID: 17600342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.
    Inoue K; Umehara T; Ruegg UT; Yasui F; Watanabe T; Yasuda H; Dumont JM; Scalfaro P; Yoshiba M; Kohara M
    Hepatology; 2007 Apr; 45(4):921-8. PubMed ID: 17393519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.
    Yang F; Robotham JM; Grise H; Frausto S; Madan V; Zayas M; Bartenschlager R; Robinson M; Greenstein AE; Nag A; Logan TM; Bienkiewicz E; Tang H
    PLoS Pathog; 2010 Sep; 6(9):e1001118. PubMed ID: 20886100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Structural Model of NS5A Protein from Hepatitis C Virus and Modulation by Mutations Confering Resistance of Virus Replication to Cyclosporin A.
    Badillo A; Receveur-Brechot V; Sarrazin S; Cantrelle FX; Delolme F; Fogeron ML; Molle J; Montserret R; Bockmann A; Bartenschlager R; Lohmann V; Lippens G; Ricard-Blum S; Hanoulle X; Penin F
    Biochemistry; 2017 Jun; 56(24):3029-3048. PubMed ID: 28535337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility.
    Ansari IU; Allen T; Berical A; Stock PG; Barin B; Striker R
    Virology; 2013 Feb; 436(2):268-73. PubMed ID: 23290631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse effects of cyclosporine on hepatitis C virus strain replication.
    Ishii N; Watashi K; Hishiki T; Goto K; Inoue D; Hijikata M; Wakita T; Kato N; Shimotohno K
    J Virol; 2006 May; 80(9):4510-20. PubMed ID: 16611911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
    Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
    Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.